The effects of N-methyl-D-aspartate (NMDA) on opioid receptor-mediated G protein activation were explored in neuroblastoma X glioma hybrid (NG108 -15) cells. Treatment of the cells with NMDA resulted in a remarkable attenuation of -enkephalin (DPDPE), a ␦-opioid receptor agonist. The effects of NMDA were dose and time dependent with an IC 50 value of 5 nM and could be blocked by NMDA receptor antagonists. After NMDA treatment, the DPDPE dose-response curve shifted to the right (EC 50 value increased ϳ7-fold, from 6 to 40 nM), and the maximal response induced by DPDPE was reduced by ϳ60%. The effects of NMDA were reversible, and the DPDPE response could recover within 60 min. The functional responses of ␦-, -, and -opioid receptors in primarily cultured neurons also were attenuated significantly by NMDA treatment. The inhibitory effects of NMDA on opioid receptormediated G protein activation could be blocked by coadministration of the protein kinase C (PKC) inhibitors or by elimination of the extracellular Ca 2ϩ . Correspondingly, NMDA treatment of NG108 cells significantly elevated cellular PKC activity and stimulated G i␣2 phosphorylation. Transient transfection into NG108 -15 cells of the wild-type G i␣2 and a mutated G i␣2 (Ser144Ala) resulted in a 2-fold increase in DPDPE-stimulated G protein activation. The DPDPE responses were greatly inhibited by NMDA treatment in the wild-type G i␣2 -transfected cells but much less affected in the mutant G i␣2 -transfected cells. In summary, NMDA attenuates opioid receptor/G protein coupling, and this process requires activation of PKC.
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Opiates are the therapeutic mainstay of clinical pain management, and they have many other important physiological effects. Pharmacological studies have defined three major types of opioid receptors (designated ␦, , and ), all of which are coupled to PTX-sensitive G proteins (G i /G o ) and regulate adenylyl cyclase, Ca 2ϩ channels, and potassium channels (Hescheler et al., 1987; McKenzie and Milligan, 1990) . A prominent characteristic of opiates is their ability to induce drug tolerance and dependence, and the side effects greatly limit their therapeutic efficacy. Although it is suggested that receptor desensitization, internalization, and down-regulation may be involved, the mechanisms underlying opioid tolerance and dependence are not well understood (Louie et al., 1986; Nestler, 1996) .
There is accumulating evidence that the NMDA receptor plays a role in opioid analgesia, tolerance, and dependence.
In animal and clinical studies, various NMDA receptor antagonists profoundly attenuate opioid tolerance and dependence Akil, 1991, 1994; Gutstein and Trujillo, 1993) , and the NMDA receptor antagonist ketamine has been found to potentiate the analgesic effects of morphine in patients with cancer (Mercadante et al., 1995) . These suggest that NMDA antagonists may be a promising weapon in combating the addictive and abuse characteristics of opiates, and it is worthwhile to investigate the cellular and molecular mechanisms of cross-talking between the NMDA receptor system and the opioid receptor system. Neuroblastoma ϫ glioma hybrid (NG108 -15) cells have been used as a good model to study the interaction between the NMDA receptor and opioid receptors (Louie et al., 1986 , Ohkuma et al., 1994 . We demonstrated that activation of the NMDA receptor attenuated DOR-mediated inhibition of adenylyl cyclase (Cai et al., 1997) , indicating the existence of cross-talk between NMDA and opioid receptor signaling pathways at cellular level. However, it is still not known, at the molecular level, how NMDA affects the signaling of opi-oid receptors. It has been suggested that NMDA may act on the upstream of adenylyl cyclase but not directly on opioid receptors (Cai et al., 1997) . Therefore, in the current study, we focused on the opioid receptor/G protein coupling, and the results showed that NMDA attenuates opioid receptor-mediated G protein activation, possibly through PKC-mediated phosphorylation of the opioid receptor-coupled G proteins.
Materials and Methods
Cell culture. NG108-15 cells were cultured with Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum (GIBCO BRL, Gaithersburg, MD), 10% calf serum (GIBCO BRL), 0.1 mM hypoxanthine, 1 M aminopterin, and 16 M thymidine as described previously (Cai et al., 1996) . Dissociated brain neurons obtained from neonatal mice were cultured in basal Eagle's medium (GIBCO BRL) supplemented with 10% fetal calf serum (GIBCO BRL) and 10% calf serum (GIBCO BRL) as described previously (Eva et al., 1992) .
Exogenous expression of G i␣2 in NG108-15 cells. Human G i␣2 was cloned from human brain cDNA (Beals et al., 1987) , and the influenza hemagglutinin epitope (YPYDVPDYA) recognized by monoclonal antibody 12CA5 was added to the amino terminus of G i␣2 through PCR. The 5Ј primer sequence was GCG AAG CTT ATG TAC CCA GAC GTC CCA GAC TAC GCC GCG TGC ACC GTG AGC GCC, containing a HindIII restriction site before the start codon; and the 3Ј primer sequence was CGC TCG AGC CTC AGA AGA GGC AGC AG, containing an XhoI restriction site after the stop codon. G i␣2 antisense cDNA was generated by subcloning the wild-type G i␣2 cDNA reversibly into pcDNA3. The mutant G i␣2 constructs G i␣2 (Ser144Ala) and G i␣2 (Ser16Ala) were generated from the wild-type G i␣2 by site-directed mutagenesis using PCR (Vallette et al., 1989) to introduce the mutation Ser144 or Ser16 to alanine. A nonsense cDNA was produced by shifting the reading frame of G i␣2 cDNA. Wild-type G i␣2 , tagged-G i␣2 , and the mutated G i␣2 cDNAs, which were verified with dideoxy DNA sequencing, were subcloned into pcDNA3 (InVitrogen, San Diego, CA) and transfected into NG108-15 cells individually using the Ca 2ϩ phosphate precipitation method. The exogenous expression of G i␣2 was determined by Western blot analysis using a specific anti-G i␣2 antibody (NeoMarkers, Fremont, CA).
[ 35 S]GTP␥S binding assay. The experiments were performed as described previously (Traynor and Nahouaki, 1995; Cheng et al., 1997) . Briefly, cells were lysed in buffer containing 5 mM Tris⅐HCl, pH 7.5, 5 mM EDTA, and 5 mM EGTA, and the cell lysate was centrifuged at 30,000 ϫ g for 10 min. Membranes (containing 50 g of protein) were incubated in 50 mM Tris⅐HCl, pH 7.5, 5 mM MgCl 2 , 1 mM EGTA, 100 mM NaCl, 50 M GDP, and 8 nM [ S]GTP␥S (1200Ci/mmol; DuPont-New England Nuclear, Boston, MA) in a total volume of 0.1 ml at 30°for 1 hr. The reaction was terminated by dilution in phosphate-buffered saline and filtration through GF/C filters under a vacuum. Bound radioactivity was determined with a liquid scintillation counter. Basal binding was assessed in the absence of the agonists, and nonspecific binding was determined in the presence of 10 M GTP␥S. cAMP assay. The cells (ϳ1 ϫ 10 5 cells) were challenged with control medium or medium containing NMDA (Sigma) at 37°for 5 min. Then, cells were treated further with agonists in the presence of 10 M forskolin (Sigma) and 500 M 1-methyl-3-isobutylxanthine (Sigma) at 37°for 10 min. The reaction was terminated with 1 N perchloric acid and neutralized with 2 N K 2 CO 3 ; the cAMP levels of each sample were measured using radioimmunoassay as described previously (Cai et al., 1997) . Values were calculated as 100
Where cAMP (Forϩagonist) is cAMP accumulation in the presence of forskolin and agonist, cAMP (basal) is accumulation in the absence of forskolin and agonist, and cAMP (For) is accumulation in the presence of forskolin alone. Protein content of each sample was determined using the modified Bradford-Pierce assay (Pierce Chemicals, Rockford, IL).
Measurement of PKC activity. NG108-15 cells were challenged with 0.1 M PMA, 1 M NMDA, 1 M NMDA plus 1 mM APV, or 1 M NMDA plus 2 mM EGTA without Ca 2ϩ , all at 37°for 10 min. The cells were homogenized in the lysis buffer of 25 mM Tris⅐HCl, pH 7.5, 0.5 mM EDTA, 0.5 mM EGTA, 10 mM ␤-mercaptoethanol, 1 g/ml leupeptin, 1 g/ml aprotinin, and 0.5 mM phenylmethylsulfonyl fluoride. The cell membranes, which were obtained after centrifugation at 100, 000 ϫ g, were solubilized in the lysis buffer containing 0.5% Triton X-100 for 1 hr. An aliquot of supernatant was measured after centrifugation for PKC activity. The activity of PKC was measured using the SignaTECT PKC Assay System (Promega, Madison, WI) according to manufacturer's protocols.
Phosphorylation of G i␣2 . Phosphorylation was carried out as described previously (Migeon et al., 1994; Strassheim and Malbon, 1994) . At 48 hr after transient transfection with the tagged G i␣2 , NG108-15 cells were labeled at 37°for 60 min with 100 Ci/ml [ 32 P]orthophosphate (5000 Ci/mmol; DuPont-New England Nuclear) in phosphate-free Dulbecco's modified Eagle's medium (GIBCO BRL). The labeled cells were stimulated without or with 1 M NMDA, 1 M NMDA, plus the PKC inhibitor or with 1 M NMDA plus the NMDA receptor antagonist for 15 min at 37°. After stimulation, the cells were harvested by centrifugation (100 ϫ g, 2 min). A pellet of cells (10 6 /ml) was lysed by the addition of 1 ml of RIPA ϩ buffer containing 150 mM NaCl, 50 mM Tris, pH 8.0, 5 mM EDTA, pH 8.0, 1% (v/v) Nonidet P-40, 0.5% (w/v) deoxycholate, 10 mM NaF, 10 mM disodium pyrophosphate, 2 mM phenylmethylsulfonyl fluoride, 10 g/ml leupeptin, 10 g/ml aprotinin, and 0.1% (w/v) SDS. Then, 800 l of supernatant from a 15-min, 360,000 ϫ g centrifugation was adsorbed through incubation with 100 l of presoaked Protein A/Sepharose beads (Pharmacia Biotech, Uppsala, Sweden) and 1 g of 12CA5 antibody. Beads were washed three times, and immunoprecipitated proteins were dissociated from beads with 30 l of 1ϫ SDS-polyacrylamide gel loading buffer (2% SDS, 25 mM Tris, pH 6.8, 5% glycerol, 0.5% 2-mecaptoethanol, and 0.005% bromphenol blue). Then, 20 l of immunoprecipitated proteins was subjected to 10% SDS-polyacrylamide gel electrophoresis. The gels were dried and subjected to analysis with a PhosphorImager (Molecular Dynamics, Sunnyvale, CA) to determine G i␣2 phosphorylation. The amount of G proteins loaded onto each lane was examined by means of Western blot analysis in a parallel experiment using anti-G i␣2 antibody (NeoMarkers, Fremont, CA). Statistical analysis. Each experimental point was measured in at least triplicate, and at least three experiments were carried out. Data are expressed as mean Ϯ standard error of all determinations. Statistical significance of the experimental results was obtained with Student's t test (StatView). p Ͻ 0.05 was accepted as denoting statistical significance.
Results
Attenuation of DPDPE-stimulated G protein activation by NMDA. [ 35 S]GTP␥S binding assay has been proved to be an effective method to probe agonist-dependent activation of membrane-associated G proteins (Hilf et al., 1989; Lazareno et al., 1993; Tian et al., 1994; Traynor and Nahouaki, 1995) . As shown in Fig. 1 (Fig. 1) , and the maximal effects were achieved in 15 min (Fig. 1B) . The DPDPE dose-response curve shifted to the right, and the EC 50 value of DPDPE increased ϳ7-fold (from 6 to 40 nM) in response to NMDA treatment ( Fig. 2A) . After NMDA treatment, the DPDPE response recovered within 60 min (Fig. 2B) , indicating that the inhibitory effects of NMDA were reversible.
To examine whether the NMDA effects were mediated through NMDA receptor, the NMDA receptor antagonists APV and ketamine were used 5 min before NMDA application. In the presence of APV, which did not affect DPDPE response as shown in Fig. 3A , the attenuation by NMDA of DPDPE-stimulated [
35 S]GTP␥S binding was blocked (Fig.  3B) . Another NMDA receptor antagonist, ketamine (100 M), which did not alter basal DOR signaling, also blocked the inhibitory effects of NMDA (data not shown). These data indicate that the effects of NMDA were mediated through NMDA receptor.
Involvement of PKC in the inhibitory effects of NMDA on DPDPE-stimulated G protein activation in NG108-15 cells. Next, we sought to determine whether two major protein kinases, PKC and PKA, were involved in the inhibitory effects of NMDA on opioid receptor-mediated G protein activation. In the parallel experiment, pretreatment of NG108-15 cells with 0.1 M PMA, a PKC activator, displayed significant attenuation of DPDPE-stimulated [ 35 S]GTP␥S binding, which was comparable to that of NMDA (Fig. 4A) . Furthermore, treatment with the specific PKC inhibitors chelerythrine chloride (15 M) (K i ϭ 0.66 M; Calbiochem, San Diego, CA) or Gö 6976 (0.2 M) (K i ϭ 0.008 M; Calbiochem) could totally block the inhibitory effects of not only PMA but also NMDA (Fig. 4A ). However, PKA inhibitor H-89 (1.2 M; K i ϭ 0.048 M; Calbiochem) failed to block the effects of NMDA (Fig. 4A) , suggesting an essential role of PKC in the inhibitory effects of NMDA on opioid-stimulated G protein activation.
NMDA receptor is a ligand-dependent ion channel of high Ca 2ϩ permeability (MacDermott et al., 1986) . It raises the possibility that NMDA exerts its effects by mobilizing Ca 2ϩ and consequently activating Ca 2ϩ -dependent PKC. As shown in Fig. 4B -dependent PKC may be involved.
Attenuation by NMDA of functional responses of -, ␦-, and -opioid receptors in primarily cultured neu- Fig. 1 rons. Primarily cultured neurons from neonatal mice, which express NMDA receptor and all three opioid receptor subtypes, were used to determine whether NMDA also affects functional responses of ␦-, -, and -opioid receptors. After the cells were treated with 1 M NMDA at 37°for 15 min, the inhibition of cAMP accumulation induced by DPDPE, DAGO, or U69593, the specific agonist of ␦-, -, and -opioid receptor, respectively, was significantly attenuated, which was blocked by Gö 6976 (0.2 M) (Fig. 5A) . Stimulation of [ 35 S]GTP␥S binding by these three agonists also was reduced in the neuronal cells treated with NMDA for 15 min, and the inhibitory effects of NMDA also were blocked by coadministration of 0.2 M Gö 6976 (Fig. 5B) .
Activation of PKC by NMDA or PMA in NG108-15 cells. The PKC activity after NMDA or PMA pretreatment of NG108-15 cells was measured directly. As shown in Fig. 6 , challenge of the cells with NMDA resulted in a remarkable elevation of membrane-associated PKC activity (ϳ40% over basal), which was comparable to the elevation by PMA treatment (60% over basal). The stimulation of PKC activity by NMDA was significantly blocked by NMDA receptor antagonist APV (1 mM) or by the removal of extracellular Ca 2ϩ with 2 mM EGTA (Fig. 6 ), indicating mediation through NMDA receptor and involvement of Ca 2ϩ influx.
Phosphorylation of G i␣2 in response to NMDA treatment. The above data demonstrate an essential involvement of PKC in the inhibitory effects of NMDA on opioid receptor/G protein coupling. Agonist binding to ␦-opioid receptor was not changed and an increase in phosphorylation of ␦-opioid receptor was not observed after NMDA treatment (Cai et al., 1997) . G proteins that couple to opioid receptors are therefore a likely target of the NMDA effects. It has been shown that the functional response of DOR is mediated largely by G i␣2 (McKenzie and Milligan, 1990) . In NG108-15 cells pretreated with 100 ng/ml PTX for 24 hr, DPDPE-stimulated GTP␥S binding was blocked completely (Fig. 7A) . Transfection with G i␣2 antisense cDNAs resulted in a remarkable attenuation of the DOR response (Fig. 7B) , whereas transfection with a nonsense cDNA did not affect the function and expression of G i␣2 (Fig. 7, B and C) , indicating that G i␣2 was one of the major transducer of DOR. To explore the possible role of G protein phosphorylation in this cross-regulation, we metabolically labeled NG108-15 cells transiently transfected with the epitope tagged G i␣2 with [
32 P]orthophosphate followed by immunoprecipitation with antibody 12CA5 and ob- served the effects of NMDA on phosphorylation of G i␣2 . NMDA treatment led to significant phosphorylation of G i␣2 (Fig. 8A, lane 2) in comparison with the control (Fig. 8A, lane   1) . Fig. 8B showed that equal amounts of proteins were loaded onto each lane. As shown in Fig. 8C, [ 32 P] incorporation into G i␣2 increased Ͼ5-fold after NMDA treatment. The G i␣2 phosphorylation was blocked by the PKC inhibitor chelerythrine chloride (Fig. 8A, lane 3) or by the NMDA receptor antagonist APV (Fig. 8A, lane 4) .
Attenuation of the NMDA effects in NG108-15 cells transfected with mutated G i␣2 (Ser144Ala). To assess a potential correlation between NMDA-induced G protein phosphorylation and the inhibitory effects of NMDA on opioid receptor function, two mutated G i␣2 constructs (Ser144Ala or Ser16Ala) were generated using PCR. Transfection of both wild-type and the two mutated G i␣2 constructs resulted in ϳ10-fold overexpression of the proteins (data not shown), and the DPDPE responses were increased Ն60% in the transfected cells. Interestingly, the increased DPDPE responses were suppressed to the same levels by NMDA treatment in wild-type and G i␣2 (Ser16Ala)-, but not G i␣2 (Ser144Ala)-, transfected cells as that in control cells (Fig. 9) . These results strongly support the hypothesis that phosphorylation of G proteins that couple to opioid receptors is responsible for the inhibitory effects of NMDA on the functional responses of opioid receptors.
Discussion
Based on our previous results that activation of NMDA receptor attenuated opioid receptor-mediated inhibition of adenylyl cyclase activity (Cai et al., 1997) , we explored possible mechanisms for the inhibitory effects of NMDA on the functional response of opioid receptors. The fact that neither opioid binding to the receptors nor adenylyl cyclase activity was affected by NMDA treatment (Cai et al., 1997) suggests that NMDA may act on the upstream region of adenylyl cyclase in the signaling pathway of opioid receptors. In the current study, we clearly demonstrated that NMDA doseand time-dependently attenuated DPDPE-stimulated activation of G proteins in NG108 -15 cells and that NMDA also attenuated the responses mediated by -, ␦-, and -opioid receptors in primarily cultured neurons. These data indicate that NMDA does attenuate opioid receptor/G protein coupling. At the concentration of NMDA used, the effects of NMDA were reversible and were blocked by the NMDA receptor antagonists, which excludes the possibility of toxic effects of NMDA on the functional responses of opioid receptors. The EC 50 value of NMDA obtained in our experiment is apparently lower than that reported by other authors (Moran and Rivera, 1992) , possibly due to different methods and different experiment conditions.
NMDA receptor is one type of ion channel that is highly permeable to Ca 2ϩ , and activation of NMDA receptor by its specific agonist induces Ca 2ϩ influx in NG108 -15 cells (MacDermott et al., 1986) . Elevation of intracellular Ca 2ϩ is required for activation of a family of PKC (Nishizuka et al., 1992) . It is logical to hypothesize that activation of PKC via Ca 2ϩ influx would be a prerequisite for the NMDA effects. This has been strongly supported by our current results that PKC activity was increased significantly in response to NMDA treatment, the inhibitory effects of NMDA on DP-DPE-mediated activation of G proteins were blocked by PKC inhibitor but not by PKA inhibitor, and removal of extracellular Ca 2ϩ abolished not only the inhibitory effects of NMDA but also the stimulation of PKC activity by NMDA. It can be suggested that PKC is essentially involved in the inhibitory effects of NMDA on opioid receptor-mediated G protein activation.
NMDA-mediated activation of PKC could attenuate opioid receptor/G protein coupling at the level of the receptor, G proteins, or both. Because agonist binding to DOR was not changed and phosphorylation of DOR was not observed after NMDA treatment (Cai et al., 1997) , G proteins that couple to opioid receptors are a likely target of the effects of NMDA. Previous studies have shown that DOR couples to three types of G protein ␣ subunits (G i␣2 , G o␣2 , and one isoform of G i␣3 ) in NG108 -15 cells (Roerig et al., 1992) , whereas the functional response is mediated largely by G i␣2 (McKenzie and Milligan, 1990) . The current results further demonstrated that in NG108 -15 cells transfected with an antisense G i␣2 cDNA, DPDPE-stimulated G protein activation was attenuated remarkably, supporting that G i␣2 is one of the major transducer of DOR, although because transfection of the G i␣2 cDNA resulted in a ϳ10-fold overexpression of the protein and DPDPE-stimulated G protein activation was enhanced ϳ1.6-fold, it is suggested that G i␣2 may not the limiting factor in promoting GTP␥S binding after DPDPE stimulation.
Phosphorylation and inactivation of G i␣2 by direct stimulation of PKC have been documented (Bushfield et al., 1990a (Bushfield et al., , 1990b (Bushfield et al., , 1990c Strassheim and Malbon, 1994; ) . Metabolic labeling and immunoprecipitation of G i␣2 from cell extracts provide an useful tool for us to address the role of protein . Cell extracts containing equal amount of proteins were subjected to immunoprecipitation with 12CA5 antibodies. Aliquots of the precipitates were resolved on SDS-polyacrylamide gels and subjected to phosphorimaging. B, Immunoblotting of the G i␣2 content. In a parallel experiment, equal amount of the precipitates were subjected to SDS-polyacrylamide gels, followed by electrotransfer to nitrocellulose membranes and immunoblotting using antibody against G i␣2. C, Quantification of [ phosphorylation on G i␣2 . Using this method, we observed phosphorylation of G i␣2 in the cells after NMDA treatment and the blockade of NMDA-induced G i␣2 phosphorylation by APV or chelerythrine chloride. These data indicated that NMDA-induced phosphorylation of G i␣2 was mediated by NMDA receptor and through activation of PKC. It has been reported that on G i␣2 , Ser144, which is highly conserved in the ␣ subunits of both G i and G o proteins, is the major phosphorylation site of PKC (Morris et al., 1994) . Transfection of the mutated G i␣2 in which Ser144 was replaced by an alanine resulted in a remarkable attenuation of the inhibitory effects of NMDA on the DOR function. In contrast, in the cells transfected with another G i␣2 mutant (Ser16Ala), in which Ser16 is not reported to be a PKC phosphorylation site, the inhibitory effects of NMDA were not changed significantly. Our data thus suggest a possible correlation between NMDA-induced PKC activation and attenuation of opioidreceptor-mediated activation of G proteins.
The current data demonstrated only the disruption by NMDA of DOR/G protein coupling in general. It will be of interest to determine whether NMDA treatment prevents the physical association of the G protein ␣ with ␤␥ subunits, the association of the heterotrimeric G protein with the DOR, or the binding of GTP␥S to the receptor-bound G proteins. Although phosphorylation of G i␣2 may be an important step in mediating the effects of NMDA on DOR coupling, the incomplete abrogation of the effects of NMDA suggests alternate sites of regulation by NMDA beyond Ser144 on G i␣2 . Moreover, on the basis of the disparity between protein levels and DOR coupling when G i␣2 was overexpressed as mentioned, it is postulated that G i␣2 probably is not the limiting factor in promoting GTP␥S binding to the cell membranes in the presence of DPDPE. It is necessary to explore further the possible involvement of other components, perhaps G ␤␥ subunits or G i␣3 or G o␣ , in the effects of NMDA.
